AI-generated · cited to primary sources · not investment advice
Cipla (500087) Jan 2026 Filing Analysis
Does management do what it says?
North America revenue for Q2 FY26 reached $233 million, significantly outperforming the $220 million baseline target set in earlier periods. (1 exceeded across 1 tracked commitment)
“However, we expect normalization by next quarter.”
Management plans to launch two major respiratory products and one smaller respiratory launch within the next 6 months. — target: 3 respiratory launches (+4 more commitments)
“So, effectively, I think what is immediate, let's say from 0 to 6 months, we are calling for, from 0 to 6 months, two big respiratory launches, and one smaller launch, right, on respiratory.”
See the full cited Management analysis of Cipla
How durable is the business?
The One-India business reached a major milestone, surpassing INR 11,000 crores in annual revenue. Growth was driven by branded prescriptions, trade generics, and consumer health, despite seasonal challenges in acute categories. (5 expanding across 1 engine)
“Our One-India business delivered a strong quarter with 10% year-on-year growth, reinforcing its momentum and commitment to sustainable long-term growth.”
Cipla's chronic therapy mix in India improved further to 61.5%, strengthening its defensive moat. Its leading inhalation brand, Foracort, became the first in the Indian Pharmaceutical Market to cross INR 900 crores. (5 expanding)
“Our overall chronic mix further strengthened to 62.3% YOY... Cipla continues to be the largest pharma company in terms of volume and the only brand with 2 billion plus unit sales in IPM”
North America revenue saw a significant recovery and reached an all-time high annual revenue of $934 million. The segment is transitioning from a period of decline to growth, supported by new drug approvals and supply normalization for Lanreotide. (5 expanding)
“Cipla continues to hold number one position in the overall U.S. Albuterol MDI market this quarter, with our market share at 22%... our pipeline includes four significant respiratory launches”
The EMEU business has officially entered a growth phase after four years of stability, driven by deep market penetration and expansion in both direct-to-market (DTM) and business-to-business (B2B) categories. (5 expanding across 1 engine)
“In EMEU, we delivered our fourth successive quarterly revenue above $100 million, recording a 7% YOY growth in USD terms.”
The company's cash position has strengthened significantly, reaching over $1 billion in net cash, providing a massive buffer for future growth investments. (2 expanding across 1 engine)
“We reported a quarterly revenue of Rs 7,074 crores, which is flat YOY. The EBITDA margin, excluding other income, stood at 17.7%, to be precise for the quarter.”
See the full cited Business Model analysis of Cipla
Where does growth come from?
Profitability is showing a strong upward trend. EBITDA margins improved from 24.5% in FY24 to 25.9% in FY25. The final quarter (Q4) showed a significant 150 basis point improvement compared to the same period last year, driven by better product mix and operating efficiency. (2 accelerating, 2 steady across 4 signals, 1 leading indicator)
“we entered into a strategic agreement with Pfizer for exclusive marketing and distribution rights of four well-established Pfizer brands in India. We also signed a definitive agreement to acquire Inzpera Health Sciences”
Cipla is actively expanding and de-risking its manufacturing footprint. This includes a recently capitalized China facility and preparing two U.S. facilities to supply respiratory products (MDI/DPI). (1 new trend across 1 signal, 1 leading indicator)
“let's say from 0 to 6 months, we are calling for... two big respiratory launches, and one smaller launch, right, on respiratory... Then we have peptide launches... in the 6 months to 12 months trajectory.”
The India business is showing an improving growth trend, recovering from a slower Q1. Branded prescriptions grew 8% while chronic therapies like urology and dermatology saw high double-digit growth. (1 accelerating, 1 decelerating, 3 steady across 5 signals)
“Our One-India business delivered a strong quarter with 10% year-on-year growth... Our overall chronic mix further strengthened to 62.3% YOY.”
Cipla is expanding its diabetes treatment options in India through a partnership with Eli Lilly to launch a modern once-weekly injection for obesity and diabetes.
“through our partnership with Eli Lilly, we launched Yurpeak, a modern once-weekly tirzepatide therapy for obesity and type 2 diabetes”
Cipla is actively building capacity and diversifying its manufacturing base to ensure supply resilience. The China facility is now fully utilized for US supplies, and the company is maximizing capacity for key products like Albuterol to gain market share. (1 accelerating across 1 signal)
“it’s a perpetual license that we have got for the trademark and we can also manufacture it in-house... we will have the benefit of own manufacturing and therefore full supply chain margins.”
See the full cited Future Growth analysis of Cipla
What could break the thesis?
The risk remains stable but high; while FY25 EBITDA (25.9%) exceeded guidance, management has lowered the FY26 outlook to 23.5%-24.5% specifically due to the Revlimid revenue cliff. (2 stable, 1 easing, 2 intensifying, 1 high-severity)
“of the 66 million rough decline in the US sales on a sequential basis, how much directionally we can attribute to Revlimid versus Lanreotide? Ashish Adukia: So, a significant portion of that comes from Revlimid, a major portion of that.”
The risk is INTENSIFYING as management lowered the full-year EBITDA margin guidance from 23.5%-24.5% down to 22.75%-24% due to higher R&D and the Revlimid tail-off. (3 intensifying, 2 easing, 1 high-severity)
“The EBITDA margin, excluding other income, stood at 17.7%... The decline in EBITDA margin was primarily driven by lower generic Revlimid revenues... these are deliberate strategic choices and will lead to FY’26 EBITDA margin guidance to land at around 21%.”
The regulatory risk profile is easing as the company secured its own ANDA approval for Lanreotide Injection in May 2024, potentially reducing reliance on the troubled partner facility. (1 easing, 2 stable, 1 intensifying, 1 high-severity)
“Recently, however, our partner, Pharmathen underwent a U.S. FDA inspection at their manufacturing facility, which resulted in nine 483 observations. As part of their remediation efforts, production has been temporarily paused. We currently expect Lanreotide resupply to resume in H1 FY’27.”
Margins have stabilized at 25.6% this quarter, which is above the full-year guidance of 23.5% to 24.5%, despite continued high R&D spend. (1 stable, 1 easing, 1 resolved)
“As I prepare to hand over my responsibilities, it is my privilege to invite Achin to take charge and lead the next phase of our growth and journey.”
The risk is EASING as the South Africa business grew 6% in local currency (ZAR) terms, and management expects the next two quarters to be critical for margin expansion. (2 easing, 3 resolved)
“The business-based weakness in primary revenues this quarter due to in-country channel destocking.”
See the full cited Risk analysis of Cipla
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.